ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,121.24
-0.28%
Dow Jones
37,903.29
0.23%
Gold vs US Dollar
2,326.005
0.07%
Brent Oil
83.625
0.10%
Bitcoin
57,639.72
-1.03%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Galapagos (GLPG)

  7. Galapagos (GLPG) News

Galapagos (GLPG)

Galapagos
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:GLPG
DateTimeSourceHeadlineSymbolCompany
22/02/202421:01UK RegulatoryGalapagos announces full year 2023 results and outlook for 2024LSE:GLPGGalapagos
15/02/202421:01UK RegulatoryGalapagos presents at EBMT-EHA annual meeting 2024LSE:GLPGGalapagos
31/01/202421:01UK RegulatoryGalapagos completes transaction to transfer Jyseleca® business to AlfasigmaLSE:GLPGGalapagos
06/05/201506:31GlobeNewswireGalapagos listed 10 years on Euronext Amsterdam and BrusselsLSE:GLPGGalapagos
06/05/201506:31GlobeNewswireGalapagos announces launch of proposed global offeringLSE:GLPGGalapagos
01/05/201517:00GlobeNewswireBNP Paribas notify of 4.8% shareholding in GalapagosLSE:GLPGGalapagos
01/05/201517:00GlobeNewswireGalapagos creates new warrant planLSE:GLPGGalapagos
27/04/201521:00GlobeNewswireFilgotinib as monotherapy also hits primary endpoint in DARWIN 2 trialLSE:GLPGGalapagos
15/04/201522:00GlobeNewswireGalapagos files registration statement in the United States for a proposed global offeringLSE:GLPGGalapagos
14/04/201521:00GlobeNewswireGalapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in...LSE:GLPGGalapagos
27/03/201518:29GlobeNewswirePublication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015LSE:GLPGGalapagos
27/03/201506:30GlobeNewswireGalapagos raises €5.8 million through warrant exercises, Board and Executive Committee members investLSE:GLPGGalapagos
17/03/201506:31GlobeNewswireGalapagos regains rights to GLPG1690, announces end of alliance with JanssenLSE:GLPGGalapagos
06/03/201506:35GlobeNewswireGalapagos to be included in Amsterdam Midcap IndexLSE:GLPGGalapagos
06/03/201506:31GlobeNewswireGalapagos reports 2014 financial resultsLSE:GLPGGalapagos
23/02/201506:30GlobeNewswireGalapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatmentLSE:GLPGGalapagos
16/02/201506:30GlobeNewswireGalapagos reports positive Phase 1 results for GLPG1690LSE:GLPGGalapagos
11/02/201506:31GlobeNewswireGalapagos receives €1.6 million IWT grant for hepatitis B programLSE:GLPGGalapagos
09/02/201506:31GlobeNewswireBNP Paribas notify of 5.08% shareholding in GalapagosLSE:GLPGGalapagos
22/01/201506:31GlobeNewswireGalapagos receives €2.5 million IWT grant for antibiotic researchLSE:GLPGGalapagos
21/01/201517:56GlobeNewswireDelta Lloyd notify of 4.96% shareholding in GalapagosLSE:GLPGGalapagos
09/01/201506:30GlobeNewswireVicki Sato resigns from Galapagos BoardLSE:GLPGGalapagos
08/01/201506:30GlobeNewswireGalapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patientsLSE:GLPGGalapagos
19/12/201406:31GlobeNewswireGalapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVieLSE:GLPGGalapagos
16/12/201406:32GlobeNewswireGalapagos regains full rights to GPR84 inhibitor GLPG1205LSE:GLPGGalapagos
12/12/201406:31GlobeNewswireGalapagos selects second component of its investigational cystic fibrosis combination treatmentLSE:GLPGGalapagos
08/08/201406:30GlobeNewswireGalapagos cash position of €232 M provides solid basis for R&D pipeline investmentLSE:GLPGGalapagos
05/08/201406:31GlobeNewswireGalapagos receives milestone in osteoarthritis alliance with ServierLSE:GLPGGalapagos
25/07/201417:00GlobeNewswireGalapagos creates new warrant planLSE:GLPGGalapagos
23/07/201406:30GlobeNewswireMorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical DevelopmentLSE:GLPGGalapagos
 Showing the most relevant articles for your search:LSE:GLPG

Your Recent History

LSE
FMET
Fulcrum Metals
LSE
VLX
Volex
LSE
BIRD
Blackbird
LSE
EDEN
Eden Research
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved